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Abstract
Prostate-specific antigen (PSA) two-dimensional electrophoresis (2-DE) subforms (F1–F5) have been described to
be altered in prostate cancer (PCa) compared to benign prostatic hyperplasia (BPH). To understand their mo-
lecular differences, characterization of these subforms from PCa serum and seminal plasma, namely, at the
glycan level, was performed. PSA 2-DE subforms from two serum PCa samples and seminal plasma were
analyzed by N-glycan sequencing using high-performance liquid chromatography (HPLC) combined with
exoglycosidase array digestions and by mass spectrometry. F1, F2, and F3 subforms showed the same N-glycan
pattern, which contained higher levels of sialic acid than the F4 subform, whereas the F5 subform was un-
glycosylated. When comparing PSA subforms from PCa with seminal plasma, a decrease in sialylation was
observed. Furthermore, the analysis of F3, the more abundant PSA subform, showed a higher proportion of
alpha 2–3 sialic acid and a decrease in core fucosylated glycans in the PCa sample. These N-glycan changes in
PCa PSA subforms highlight the importance of glycosylation as an indicator of PCa disease.
Introduction
Prostate-specific antigen (PSA) is the tumor markercurrently used in prostate cancer (PCa) screening and
diagnosis. However, its use is controversial, as serum PSA
levels are also increased in other nonmalignant prostatic dis-
eases such as benign prostatic hyperplasia (BPH) (Bracarda
et al., 2005). To address this issue, there have been several
attempts to improve PSA specificity focusing on the mea-
surement of different forms of PSA found in serum.
PSA is a glycoprotein produced by the prostatic epithelium
and it is secreted as a proenzyme (proPSA) into the lumen of
the prostate gland where it is activated. It is a normal com-
ponent of seminal plasmawhere it is present at relatively high
concentrations (0.5–3mg/mL) (Diamandis, 1998). In prostate
disease, the basement membrane can be disrupted, and PSA
can access the peripheral circulation and be detected in
the blood. The predominant molecular PSA form found in
blood is complexed with protease inhibitors, mainly alpha-1-
antichymotrypsin (ACT) (Balk et al., 2003). The remaining
PSA forms are inactive and circulate as free PSA (fPSA). These
include proPSA forms and internally cleaved PSA such as
BPSA (BPH associated PSA) (Mikolajczyk et al., 2002).
Measurements of complex PSA (Brawer et al., 1998), fPSA
(Catalona et al., 2000), specific free PSA forms such as proPSA
(Mikolajczyk et al., 2004) and BPSA (Linton et al., 2003) have
been studied to improve the specificity of PCa detection.
However, only the percentage of PSA circulating in the free
form (%fPSA) has been widely used by clinicians as a diag-
nostic tool in patients with low tPSA levels (Loeb and Cata-
lona, 2008).
Other studies to improve the specificity of PSA in PCa di-
agnosis have focused on some of the biochemical character-
istics of PSA. For example, glycosylation of PSA has been
reported to be altered in the presence of tumors. In fact, se-
creted glycoproteins can reflect the changes in glycosylation
pattern that usually take place on the tumor cells surface
(Peracaula, 2007; Varki et al., 2008). Several authors have
described modifications in the sialylation pattern of PSA de-
rived from malignant origins compared with that from heal-
thy individuals (Huber et al., 1995; Ohyama et al., 2004;
Peracaula et al., 2003; Tabares et al., 2006). Sialic acid is a
negatively charged carbohydrate. An increase or decrease in
the content of this monosaccharide on a PSA N-glycan chain
can modify the PSA’s isoelectric point (pI). Two-dimensional
gel electrophoresis has been used to evaluate sialic acid var-
iations in PSA from different sources (Charrier et al., 1999;
Isono et al., 2002; Jung et al., 2004; Tabares et al., 2007).Most of
these studies have focused on fPSA 2-DE subforms, which
represent only 10–30% of the total serum PSA. To enable the
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analysis of all serum PSA subforms, we developed a sensitive
and precise method to evaluate PSA 2-DE subforms from PCa
and BPH sera, which included an initial ethanolamine treat-
ment step to release PSA bound to ACT. Five individual PSA
2-DE subforms (called F1, F2, F3, F4, and F5) were detected
and some were significantly altered between BPH and PCa
patients. Compared to BPH, the relative percentage of F3
(%F3) negatively correlated with the stage of cancer, while the
relative percentage of F4 (%F4) correlated positively with the
stage of cancer. %F3 demonstrated a tendency for higher
specificity and sensitivity than the currently used tPSA and %
fPSA tests to distinguish between the two groups of patients
(Sarrats et al., 2010).
The aim of the present study has been to unravel the bio-
chemical differences among these PSA subforms (F1, F2, F3,
F4, and F5) to develop future clinical assays to directly mea-
sure %F3. Thus, we have analyzed PSA 2-DE subforms from
two prostate cancer patients’ sera and also from seminal
plasma from a healthy donor using N-glycan sequencing and
mass spectrometry. Unfortunately, the biochemical analysis
of PSA 2-DE subforms from a BPH patient was not possible
due to the fact that BPH sera do not reach high enough PSA
levels to allow N-glycan sequencing analysis. Seminal plasma
was therefore taken as a source of healthy PSA.
These analyses have enabled us to characterize differ-
ences among the PSA 2-DE subforms (F1–F5) in each of the
samples and to compare the glycosylation pattern be-
tween the samples originating from healthy and malignant
origins.
Materials and Methods
PSA samples
Sera from two PCa patients (PCa A and PCa B) with high
tPSA content (above 2.5 mg/mL) and seminal plasma from a
healthy donor (*0.5mg/mL fPSA) were obtained from
Hospital Universitari, Dr. J. Trueta (Girona, Spain) following
the standard operating procedures of its Ethics Committee.
PCa patients were diagnosed by the Urology unit using
transrectal ultrasound-guided biopsy and both showed mul-
tiple bone metastases detected by positron emission tomog-
raphy and axial computed tomography.
PSA sample pretreatments and analyses are summarized in
Figure 1.
Serum sample pretreatment
Serum PSA complexed to ACT was released using a pre-
viously published method with modifications (Peter et al.,
FIG. 1. Schematic illustration of workflow used in this work to obtain and characterize PSA 2-DE subforms (A,B) and to
study PSA O-glycosylation (C) and phosphorylation (D). PSA IP, PSA immunopurification; 1-DE, one-dimensional elec-
trophoresis; 2-DE, two-dimensional electrophoresis; 2AB, 2-aminobenzamide; NP-HPLC, normal-phase HPLC; Protein ID,
protein identification.
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2000). A solution of 2,565mL phosphate-buffered saline (PBS)
and 265mL 2M ethanolamine (pH 12) was added to 2,850mL
of serum (up to a final pH of 10.3) and incubated at 258C for
24 h. Before PSA isolation, the mixture was neutralized with
0.5M HCl.
Total PSA was isolated by modification of a previously
described direct immunoadsorption method (Peter et al.,
1999). A suspension of 6mL of 0.72 g/L streptavidin-coated
magnetic beadswaswashed three timeswith 6mL ofwashing
buffer (50mM Tris, 150mM NaCl, pH 7.4, 1% Triton X-100)
usingmagnetic separation. The beadswere then incubated for
30min at room temperature with slight shaking with 3mL of
the biotinylated mouse monoclonal antibody anti-tPSA M-36
(Roche Diagnostics, Germany), in a final concentration of
33.3 mg/mL dissolved in incubation buffer (50mM Tris,
150mM NaCl, pH 7.4, 0.1% Tween-20, 1% BSA). Then, the
beads were washed as mentioned above and incubated for 1 h
with 5,700mL of neutralized treated serum (containing
2,850 mL of original serum). Afterward, the beads were wa-
shed as already described and the immunoadsorbed PSAwas
eluted with 360mL of 2-DE rehydration buffer (8M urea, 0.5%
Triton X-100, 13mM DTT, 1% Pharmalite 3-10 (Amersham
Pharmacia Biotech, Germany), traces of Bromophenol blue)
for 1 h.
Seminal plasma sample pretreatment
PSA from seminal plasma for MS analysis purposes was
isolated using the procedure described above with some
modifications: 4mL of 0.72 g/L streptavidin-coated magnetic
beads solutionwerewashed three timeswith 4mL ofwashing
buffer and incubated with 2mL of the biotinylated mouse
monoclonal antibody anti-tPSA M-36 (Roche Diagnostics)
(33.3 mg/mL in incubation buffer). Then, the beads were wa-
shed as mentioned above and incubated for 1 h with 4mL of
1/20 diluted seminal plasma (in incubation buffer). After-
ward, the beads were washed as already described and the
immunoadsorbed PSA was eluted with 360mL of 2-DE rehy-
dration buffer for 1 h.
One milliliter of 1/10 diluted seminal plasma was also
immunoadsorbed for phosphorylation analysis using the
same protocol as above but the elution step was performed
with 50mL of 1gel-loading buffer (30mM Tris-HCl pH 6.8,
10% (v/v) glycerol, 2% SDS, 1.25% b-mercaptoethanol, 0.01%
Bromophenol blue).
Two-dimensional electrophoresis (2-DE)
2-DE was performed according to the procedure we pre-
viously described (Sarrats et al., 2010). Active in-gel rehy-
dration was effectuated with Immobiline dry strips pH 3–10,
18 cm (GE Healthcare, Sweden) using the 360 mL of the im-
munopurified PSA samples eluted in 2-DE rehydration buffer
or 50mL of seminal plasma diluted in 360 mL of 2-DE rehy-
dration buffer. Following electrophoresis, 2-DE gels were
stained by Coomassie blue and PSA spots were excised, cut
into 1mm3 pieces and kept at 208C until analysis (Royle
et al., 2006).
The pI assignment to each PSA spot was calculated by
measuring the spot distance to the anodic edge and trans-
forming it into a pI value according to the relation between
distance and pI supplied by the manufacturer.
N-glycans analysis
N-Glycans release, extraction and 2-aminobenzamide
(2-AB) labeling. N-Glycans were released and extracted
from the 1-mm3 gel pieces of PSA spots according to the
procedure described by Royle et al. (2006). Briefly, the gel
pieces were washed and treated with PNGaseF to release the
N-linked glycans. Afterward, N-glycans were fluorescently
labeled with 2-aminobenzamide (2AB) by reductive amina-
tion (Bigge et al., 1995) (LudgerTag 2-AB labeling kit Lud-
gerLtd, Abingdon, UK).
Simultaneous oligosaccharide sequencing by exoglycosi-
dase digestions. The 2AB-labeled glycans were digested in
10mL of 50mM sodium acetate buffer, pH 5.5 for 18 h at 378C,
using arrays of the following enzymes (all purchased from
Prozyme, San Leandro, CA, USA) at the indicated concen-
trations: ABS—Arthrobacter ureafaciens sialidase (EC 3.2.1.18),
0.5U/mL; NAN I— Streptococcus pneumoniae sialidase
(EC 3.2.1.18), 1.7U/mL; BTG—Bovine testes b-galactosidase
(EC 3.2.1.23), 1U/mL; SPG—Streptococcus pneumoniae b-
galactosidase (EC 3.2.1.23), 0.1U/mL; BKF—bovine kidney
alpha-fucosidase (EC 3.2.1.51), 1U/mL; GUH—Streptococcus
pneumoniae b-N-acetylglucosaminidase, recombinant in
Escherichia coli (EC 3.2.1.30), 8U/mL. After incubation,
enzymes were removed by filtration through a protein-
binding EZ filters (Millipore Corporation, Bedford, MA,
USA) (Royle et al., 2006).
Normal-phase high-performance liquid chromatography
(NP-HPLC). Undigested and digested 2-AB-labeled N-
glycans were subjected to NP-HPLC using a TSK-Gel Amide-
80 4.6250mm column (Anachem, Luton, UK) on a 2695
Alliance separations module (Waters, Milford, MA, USA)
equipped with a Waters temperature control module and a
Waters 2475 fluorescence detector. Solvent A was 50mM
formic acid adjusted to pH 4.4 with ammonia solution. Sol-
vent B was acetonitrile. The column temperature was set to
308C. Gradient conditions were a linear gradient of 20–58%A,
over 152min at a flow rate of 0.4mL/min. Samples were in-
jected in 80% acetonitrile. Fluorescence was measured at
420 nm with excitation at 330 nm. The system was calibrated
using an external standard of hydrolyzed and 2AB-labeled
glucose oligomers to create a dextran ladder. Glycans were
analyzed on the basis of their elution positions measured in
glucose units (GU) (Royle et al., 2006).
Matrix-assisted laser desportion/ionization-time
of flight (MALDI-TOF) mass spectrometry
Seminal plasma PSA 2-DE spots were in-gel digested with
trypsin (sequencing grademodified, Promega Biotech Iberica,
Spain) in the automatic Investigator ProGest robot (Genomic
Solutions, Holliston, MA, USA). Briefly, excised gels spots
were washed with ammonium bicarbonate buffer (50mM
NH4HCO3) and acetonitrile. Proteins were reduced with
10mM DTT solution during 30min, and alkylated with a
55 mM solution of iodine acetamide. After the washings with
buffer and acetronitrile, proteins were digested overnight, at
378C with 0.27 nmol of trypsin. Tryptic peptides were ex-
tracted from the gel matrix with 10% formic acid and aceto-
nitrile; the extracts were pooled and dried in a vacuum
centrifuge.
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Proteins were analyzed in a MALDI-TOF/TOF (4700 Pro-
teomics Analyzer, Applied Biosystems, IL, USA) mass spec-
trometer. The digests were redissolved in 0.1% trifluoroacetic
acid in 50% acetonitrile. Typically 0.5 to 1.0 mL of sample was
mixedwith the same volume of amatrix solution (2–5mg/mL
a-cyano-4-hydroxycinnamic acid in 50% MeCN, 0.1–0.2%
trifluoroacetic acid) and spotted to the MALDI plate. MS
spectra were acquired in positive reflector mode (voltage
of 20 kV in the source 1 and laser intensity ranged from 5,800–
6,200). Typically, 500 shots per spectrum were accumulated.
MS/MS spectra were acquired using collision-induced dis-
sociation with atmospheric air as the collision gas. A MS-MS
1-kV positive mode was used.
MS and MS/MS spectra from the same spot were merged
in a singlemascot generic file (mgf) file prior to submission for
database searching. Mgf files were submitted for database
searching in a MASCOT search engine against nonredundant
SwissProt database. The search parameters were: human
taxonomy, onemissed cleavage allowed, carbamidomethyl of
cystein as fixed modification, oxidation of methionine and
deamidation of asparagine or glutamine as variable modifi-
cations. Peptide tolerance was 100 ppm and 0.25 Da, respec-
tively, for MS and MS/MS spectra. Only proteins with scores
above significant Mascot level were considered as positive
hits.
O-Glycosylation analysis
To investigate the presence of O-glycans attached to PSA,
glycoproteins from seminal plasma (healthy donor) were di-
gested with ABS plus O-glycosidase. ABS is used to release
sialic acid residues which block O-glycosidase to access to the
oligosaccharide chain. ABS digestion and a negative control
without digestion (buffer without enzymes) were also per-
formed. Both enzymes were purchased from Roche.
A total of 4.5ng of PSA (9mL of 1/1,000 diluted seminal
plasma) were incubated in 10mL of 0.1% SDS for 10min at
708C. Then, the solution was cooled down for 3min at 48C.
After that, ABS (1U/mL) or ABS (1U/mL) with O-glycosidase
(50mU/mL) digestions were performed in 20mL of 100mM
sodium acetate buffer, pH 5.5, 1% Triton X-100 for 18h at 378C.
For the negative control of the digestion the volume of enzymes
were substituted for water.
The products of the digestions were run on a 15% SDS-
PAGE gel and then transferred to a PVDF membrane. PSA
was immunodetected as previously described (Sarrats et al.,
2010).
Phosphorylation analysis
Analysis of phosphorylation was performed using the
ProQ-Diamond phosphoprotein gel stain (Molecular Probes,
Invitrogen Corporation, Carlsbad, CA, USA), which detects
phosphate groups attached to serine, threonine, and tyrosine
residues of proteins (Schulenberg et al., 2004). A total of 25mg
of PSA was immunopurified and electrophoresed together
with 1mL of PipermintStick phosphoproteinmolecularweight
standards (Molecular Probes, Invitrogen), which contains a
mixture of two phosphorylated and four nonphosphorylated
proteins. Thus, the standards serve both for as molecular
weight markers and as positive and negative controls for the
phosphoprotein gel stain. The gel was stained according to
the standard protocol for minigels supplied by the manufac-
turer and visualized by a UV transilluminator. Then, the gel
was Coomassie stained to detect all protein bands present.
Results
N-Glycan analysis of PSA 2-DE subforms
PSA from seminal plasma (healthy donor) and from two
serum samples (PCaA and PCa B)was separated by 2-DE and
stained with coomassie to obtain PSA 2-DE subforms. The
serum samples were previously subjected to ethanolamine
treatment to release PSA bound to alpha-1-antichymotrypsin
(ACT), and then immunopurified. Five spots corresponding
to F1, F2, F3, F4, and F5 subforms of PSA could be observed.
Their experimental pIs were: 6.4, 6.6, 6.8, 7.0, and 7.2 respec-
tively. However, F5 could not be detected in any of the serum
samples analyzed (Fig. 2).
These spots were excised from the 2-DE gels and treated
with PNGaseF. N-Glycans released were 2-AB labeled and
subjected to NP-HPLC. Fourmain peaks (3–6) were present in
the N-glycan profiles from the seminal plasma PSA and the
PCa A serum PSA sample (Fig. 3). N-Glycan assignments
of these peaks were performed by exoglycosidase digestions
(data not shown). Relative areas and structures assigned
to each peak are summarized in Table 1. Peak glucose
units (GUs) corresponded to those previously described for
the whole PSA N-glycans from seminal plasma and a PCa
FIG. 2. PSA 2-DE subforms of seminal plasma from a
healthy donor (A) and of a serum from a prostate cancer
patient (PCa A) (B). Figures correspond to immunopurified
samples.
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patient (Tabares et al., 2006). Spots F1, F2, and F3 contained
mono- and disialylated complex biantennary structures, F4
contained mainly monosialylated complex biantennary
structures and F5 was found not to be N-glycosylated (Fig. 3).
This is in agreement with the lower molecular weight that F5
showed in the 2-DE gel (Fig. 2A) and with previous data from
Isono et al. (2002). In this article, spots corresponding to F1 to
F4 positively stained with Periodic acid-Schiff (PAS) carbo-
hydrate stain, whereas spot F5 did not stain, consistent with
its unglycosylated status.
F1, F2, and F3 had basically the same peak areas, and
consequently, the same proportion of mono- and disialylated
structures. Therefore, the sialic acid content in the N-glycan
chains of F1, F2, and F3 cannot account for their different pI.
The proportion of mono- and disialylated structures varied
between the seminal plasma and the serum samples. F1, F2,
and F3 seminal plasma subforms had a higher proportion of
disialylated structures (*70%) compared to serum ones
(*50%) (Table 1).
PCa B serum sample contained less amount of PSA and F2,
F3, and F4 could only be analyzed by ABS digestion (data not
shown). F2 and F3 had the sameprofile and contained a higher
amount of sialylated glycan structures than F4 in agreement
with the above results obtained for PCa A serum and seminal
plasma subforms.
The more abundant subform F3 was studied in more detail
to investigate the type of sialic acid linkage and its core fucose
content, because these have been reported to differ in PSA
from benign and malignant origins (Peracaula et al., 2003,
Tabares et al., 2006). Thus, F3 from PCa A and from seminal
plasma was digested with NANI and ABS (Fig. 4) to study
sialic acid linkages and core fucosylation, respectively. The
digestion with NANI showed a higher proportion of alpha
2–3 sialic acid in F3 from the prostate cancer sample compared
to that from the seminal plasma one (53 vs. 22%).
ABS, at the working concentration, may partially digest
O-acetylated sialic acids. In our analyses all the peaks in the
NP-HPLC profile of N-glycans extracted from the PSA sub-
foms were digested after ABS treatment; therefore, we could
say that is likely that PSA N-glycans do not contain O-acety-
lated sialic acids, althoughMS analysis would be necessary to
confirm it.
After ABS digestion, two peaks were observed and could
be assigned to A2G(4)2 (peak 1) and to F(6)A2G(4)2 (peak 2)
after a complete set of exoglycosidases (Fig. 4). The relative
area of peak 2 (F(6)A2G(4)2) was taken as measure of core
fucosylation content. In the seminal plasma sample, core fu-
cosylated structures were more abundant than in the PCa
sample A (66 vs. 46%).
MALDI-TOF MS analysis of PSA 2-DE subforms
Analysis of peptide mass fingerprints was performed on
the protein spots of the 2-DE seminal plasma gel after N-
glycans release. Data confirmed that PSA was the only gly-
coprotein significantly present in any of the spots and so it
was assumed that all N-glycans released were exclusively
from this glycoprotein.
Further MS analysis of the PSA spots was performed to
investigate possible modifications in the primary PSA se-
quence that could explain the distinct pI of the different PSA
subforms, namely, for F1, F2 and F3. For this purpose, PSA
from seminal plasma was first immunopurified and then
separated in a 2-DE gel. PSA spots were excised from the
gel and analyzed by MALDI-TOF/TOF. PSA was the only
protein identified in each spot and neithermodifications of the
FIG. 3. NP-HLPC chromatograms of N-glycans released from each PSA subform (F1–F5) of (A) seminal plasma from
a healthy donor and (B) serum from a prostate cancer patient (PCa A). See Table 1 for key legend of glycan symbols
representation.
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primary sequence nor deamidations of asparagines or gluta-
mines were detected. PSA peptides identified in each spot are
shown in Table 2. Peptides containing asparagines or gluta-
mines did not show any shift of mass from the calculated one,
andmost of themwere sequenced byMS/MS confirming that
no deamidations had taken place.
O-Glycan analysis of PSA
PSA N-glycosylation has been investigated by different
authors (Okada et al., 2001; Peracaula et al., 2003; Tabares
et al., 2006; Tajiri et al., 2008). However, no evidence of O-
linkages has been reported. To investigate whether O-glycans
could be attached to PSA and thereby contribute to the ob-
served differences in subforms pI, a Western blot of PSA from
seminal plasma digested with a combination of sialidase
(ABS) and O-glycosidase was performed and compared to
that digested with sialidase only. The bands of PSA observed
for the two digested samples showed the same molecular
mass, whichwas lower than the undigested PSA sample (data
not shown). The fact that O-glycosidase did not contribute to
the decrease of PSA molecular mass suggests that O-glycans
are most likely not present in PSA from seminal plasma.
Phosphorylation analysis of PSA
Analysis of phosphorylationwas performed using the ProQ-
Diamond phosphoprotein gel stain following electrophoresis
of immunopurified PSA. Neither PSA nor negative controls
stained positively for the presence of phospho-forms, whereas
positive controls did, as expected. All control proteins and PSA
bandswere subsequently visualized using Coomassie staining.
The intensity of Coomassie stained PSA was higher than any
of the phosphoproteins controls, suggesting that the absence of
signal for phosphorylated PSA was not due to limitations in
the amount of protein sample (data not shown).
Discussion
Analysis of PSA glycosylation from sera is a challenging
work as some of the differences between BPH and PCa serum
PSA could be due to a different glycosylation pattern of this
molecule and could therefore be exploited to improve speci-
ficity in PCa diagnosis. The low amount of PSA in sera is,
however, the limiting step to fully characterize the glycan
structures of PSA. So far, few groups have reported the de-
tailed glycan structures of serum PSA from PCa patients
(Tabares et al., 2006; Tajiri et al., 2008). Taking into account
that the PSA 2-DE subforms (F1–F5) show different propor-
tions between BPH and PCa sera (Sarrats et al., 2010), in this
work we have characterized by N-glycan sequencing these
2-DE spots of PSA samples from PCa patients’ sera. We also
performed the N-glycan analysis of the corresponding F1–F5
PSA subforms from seminal plasma to compare them with
those originating from PCa.
Table 1. N-Glycans in PSA Subforms from Seminal Plasma (Healthy Donor) and Serum (PCa A Patient)
A. Seminal Plasma (healthy donor) B. Serum sample (PCa A patient)
Peak IDa Assigmentb Structurec GUd Peak area (%) GU4 Peak area (%)
F1 F2 F3 F4 F1 F2 F3 F4
3 A2G(4)2S(6)1 8.06 0.03 10 9 7 31 8.03 0.07 18 9 8 46
4 F(6)A2G(4)2S(6)1 8.49 0.01 20 22 22 48 8.45 0.02 31 40 40 21
5 F(6)A2G(4)2S(3)2 (5a)
þ þ
8.86 0.04 33 33 35 13 8.81 0.06 39 38 37 30
A2G(4)2S(6)2 (5b)
6 F(6)A2G(4)2S(3,6)2 (6a) þ 9.26 0.01 36 37 37 7 9.23 0.02 12 13 16 3
F(6)A2G(4)2S(6)2(6b)
3þ 4 % Monosialylated glycans 30 31 28 80 49 49 47 67
5þ 6 % Disialylated glycans 70 69 72 20 51 51 53 33
aPeak ID relates to Figures 3 and 4.
bA2 biantenary; G(4), galactose (b1–4 linked); F(6) at the start of the abbreviation indicates fucose linked a1–6 to core GlcNAc; M, mannose;
S, sialic acid; sialic acid linkage: (3), a2–3 and (6), a2-6.
cSymbol representation of glycans for this table and Figures 3 and 4: GlcNAc, filled square; mannose, open circle; galactose, open diamond;
fucose, open diamond with a dot inside; sialic acid, filled star; beta linkage, solid line; alpha linkage, dotted line; unknown linkage, * ; the
linkage itself is indicated by the angle linking adjacent residues, thus 1–4-linkage, horizontal line (-); 1–3-linkage, angled line (/); 1–6-linkage, angled
line (\); 1–2-linkage, vertical line (|).
dGU values of are shown as means SD of all spots.
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Characterization of PSA 2-DE subforms
The N-glycan analysis of PSA subforms from both seminal
plasma and PCa patients’ sera showed that F1, F2, and F3
exhibited the same N-glycan pattern, which differed from F4
and F5. This may account for some of the differences in F1–F5
pI. The different content of sialic acid in the N-glycans from
F3, F4, and F5 PSA subforms correlated with their different
experimental pI detected by 2-DE. The subform F5 did not
appear to be glycosylated and had a pI of 7.2, which corre-
sponds to the theoretical one for PSA (7.26). F4 had a lower pI
(7.0), which can be explained by the presence of mainly
monosialylated N-glycans that contain negative charge. The
F3 subform showed an even lower pI (6.8). It contains a much
higher proportion of disialylated N-glycans, which would
again contribute to this further decrease in pI. However, F1,
F2, and F3 subforms all showed the same N-glycosylation
pattern despite having different pI values (6.4, 6.6 and 6.8,
respectively). Therefore, it seems likely that factors other than
N-glycosylation may be modifying the theoretical pI of PSA
(7.26), such as changes in the primary sequence or different
posttranslational modifications (PTM). Deamidation of as-
paragines or glutamines have been suggested as modifica-
tions responsible for the spot trains of some serum proteins
obtained in a 2-DE gel (Sarioglu et al., 2000). The deamida-
tion process generates negatively charged aspartic and glu-
tamic acid residues, which can modify a protein’s pI.
However, in the MS analysis of the seminal plasma PSA
Table 2. PSA Peptides Identified in Seminal Plasma PSA Spots
F1 F2 F3 F4 F5
Peptidea Sequence Cal. massb Obs. massc Obs. massd Obs. massc Obs. massc Obs. massc
25–33 IVGGWECEK 1,077.5033 1,077.4530 1,077.4723 1,077.4814 {
34–45 HSQPWQVLVASR 1,407.7491 1,407.8263 { 1,407.6949 { 1,407.7418 { 1,407.7126 { 1,407.7264 {
110–125 FLRPGDDSSHDLMLLR 1,887.9381 1,888.0737 1,887.8724 { 1,887.9420 { 1,887.9043 { 1,887.9192 {
48–68 AVCGGVLVHPQWVLTAAHCIR 2,344.2165 2,344.4065 2,344.1399 { 2,344.2327 { 2,344.1682 { 2,344.1848 {
171–191 LQCVDLHVISNDVCAQVHPQK 2,460.2122 2,460.2205
25–45* IVGGWECEKHSQPWQVLVASR 2,466.2346 2,466.1799
170–191* KLQCVDLHVISNDVCAQVHPQK 2,588.3071 2,588.2617 { 2,588.3479 { 2,588.3013 { 2,588.2996 {
138–169 VMDLPTQEPALGTTCYASGW
GSIEPEEFLTPK
3,540.6548 3,540.7874
a1 trypsin miss cleavage is indicated with *.
bCalculated mass of the peptides with carbamidomethylated cysteines and oxidated methionines.
cObserved mass of the peptides in the MALDI-TOF analysis. Peptides sequenced by MS/MS are marked with {.
FIG. 4. NP-HPLC chromatograms of N-glycans after sialidase digestions with NANI and ABS from the F3 PSA subform of
(A) seminal plasma from a healthy donor and (B) serum from a prostate cancer patient (PCa A). See Table 1 for key legend of
glycan symbols representation.
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subforms, neither modifications of the primary sequence nor
deamidations were detected. O-glycosylation was investi-
gated as a possible contributing factor to the differences in
the subforms pI. However, in our hands, O-glycan modifi-
cations were not detected in PSA. Phosphorylation has also
been described (along with glycosylation) as one of the most
common PTM that can contribute to changes in a protein’s
pI (Gorg et al., 2004). The phosphorylation status of PSAwas
therefore analyzed, but no phosphorylated residues were
detected. Other authors have suggested that the presence of
proPSA forms are constituents of the total free PSA subforms
detected in the serum by 2-DE. Tabares et al. (2007) reported
the presence of proPSA forms in some of the free PSA serum
2-DE subforms. However, in our PSA 2-DE subforms from
serum, the contribution from proPSA would be quite small
as the majority of the PSA analyzed corresponded to active
PSA previously bound to ACT. In addition, it is well known
that PSA from seminal plasma does not contain proPSA
forms (Mikolajczyk et al., 2002) and we detected the same
five PSA subforms (F1–F5) that in serum. Taken together, the
contribution of proPSA to the detected spot pattern can be
ruled out.
In summary, differences in N-glycosylation partially ex-
plain the different isoelectric points observed for the PSA
subforms, although themodifications that lead to different pIs
between F1, F2, and F3 remain unknown.
N-Glycosylation of PSA 2-DE subforms in prostate
cancer: Changes in sialylation and fucosylation
In the present study we describe a decrease of disialylated
N-glycans in F4 compared to those in F3 for both seminal
plasma and serum samples. Taking into account that the pIs of
these subforms are the same for PSA samples from PCa se-
rum, BPH serum, and seminal plasma (Sarrats et al., 2010) the
decrease in sialylation described for the PSA F4 subform is
likely to occur also in the corresponding F4 subform from
BPH serum. When comparing the percentages of these sub-
forms in BPH and PCa sera, a decrease in F3 and an increase in
F4 in PCa patients sera compared to BPH patients sera has
been reported (Sarrats et al., 2010). Taken together, a reduc-
tion in sialylation of serum PSA in PCa patients compared to
that in BPH patients is suggested. In support of this hypoth-
esis, PSA from BPH was described as possessing increased
sialylation when compared with that from PCa and LNCaP
in the work by Huber et al. (1995). The latter used chroma-
tofocusing techniques combined with sialidase digestion.
Recently, Meany et al. (2009) developed five lectin im-
munosorbant assays to analyze sialylation of total and free
serumPSA. SNA andMAA lectin assays for total PSA showed
higher electrochemiluminescence intensities in BPH patients
than PCa patients, suggesting a higher sialylation of total
serum PSA in BPH than in PCa patients.
Our previous results indicated a negative correlation be-
tween the percentage of F3 and a positive correlation between
the percentage of F4 and the PCa stage (Sarrats et al., 2010).
Thus, the potential decrease in PSA associated sialylation
might bemoremarked as the cancer becomesmore advanced.
In fact, in the prostate cancer cell line LNCaP, which was
derived from a node metastasis, a complete absence of sialy-
lated structures was reported for PSA (Peracaula et al., 2003).
A decrease in SNA reactivity on free PSA oligosaccharide
chain has also been reported in PCa patients with metastatic
tumors compared to those with localized tumors, suggesting
a relationship between the progression of this cancer and the
level of sialic acid (Kosanovic and Jankovic, 2005).
A general decrease in sialic acid content can be observed
when comparing the percentage of mono/disialylated struc-
tures between PSA spots from PCa patient serum with those
from healthy donor’s seminal plasma. Seminal plasma PSA
contains a greater proportion of disialylated structures in the
F1, F2, and F3 subforms comparedwith those fromPCa serum
PSA (Table 1). We further examined the specific sialic acid
linkage and observed an increase in alpha 2–3 linked sialic
acid in the F3 PSA subform for the PCa patient (53%) com-
pared with that from the healthy donor’s seminal plasma
(22%). These changes in this major subform may be consid-
ered representative of the whole PSA, as F3 accounts for
50–70% of all PSA subforms. The percentage of alpha 2–3
sialic acid in seminal plasma PSA was consistent with our
previous analyses (25%) (Tabares et al., 2006) andwith studies
by Ohyama and coworkers (*20%) (Ohyama et al., 2004). In
the same study, we observed a different proportion of alpha
2–3 linked sialic acid in the PSApresent in patients, whichwas
decreased in relation to that from healthy seminal plasma
(15 vs. 25%) (Tabares et al., 2006). However, our present re-
sults are more consistent with the observations made by other
authors (Ohyama et al., 2004; Tajiri et al., 2008).
The percentage of core fucosylation in the main PSA sub-
form, F3, from a PCa patient’s serum (46%) was lower than
that present in the same subform from healthy donor’s sem-
inal plasma PSA (66%). This result is consistent with our
previous work with serum PSA from a different PCa patient,
although there, the decrease in core fucosylated structures in
PCa compared to seminal plasma was more pronounced
(16 vs. 80%) (Tabares et al., 2006). In agreement with these
results, recently a decrease in the core fucosylated biantenn-
ary structure has also been reported in seminal plasma PSA
from PCa patients compared to seminal plasma from healthy
and BPH patients (White et al., 2009). These data suggest
that this N-glycan modification might be used for detecting
tumour related PSA.
These changes in PSA N-glycan chain are likely to occur
within the prostate cell, throughout the secretory pathway,
and these will probably include changes in alpha 2–3 and 2–6
sialyltransferases and in fucosyltransferases expression.
Changes in the expression of some glycosyltransferases have
been described in prostate tumor cells compared to normal
prostate tissue (Barthel et al., 2008). The study of the molec-
ular mechanisms involved in the glycosylation changes in
prostate tumor tissues, such as alteration in the glycosyl-
transferase expression pattern, would be required to explain
PSA N-glycan changes.
Conclusions
N-Glycan analysis of each PSA subform (F1–F4) from both
prostate cancer sera and seminal plasma revealed differ-
ences in N-glycan sialylation for F3 and F4 subforms. F3
(which is decreased in PCa patient sera compared to BPH)
showed both mono and disialylated N-glycans, whereas F4
(which is increased in PCa patient sera) showed mainly
monosialylated glycans in all samples analyzed. Assuming
that these N-glycan changes between F3 and F4 would also
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be present in the PSA subforms from BPH serum, the degree
of PSA sialylation might be exploited to distinguish PCa
from BPH. However, the development of assays to directly
measure sialylation and/or core fucosylation of PSA serum
is required to analyze a large set of samples and to determine
whether these PSA N-glycan changes could help to dis-
criminate between benign and malignant conditions of the
prostate.
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